Antigenics announces positive result for AG-707 to treat genital herpes

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

See the article here:
Antigenics announces positive result for AG-707 to treat genital herpes